姜黄素
炎症性肠病
脂质体
微泡
外体
医学
疾病
化学
纳米技术
药理学
内科学
材料科学
生物化学
小RNA
基因
作者
Vincenzo De Leo,Lucia Catucci,Anna Maria Maurelli,Valeria Daniello,Massimo Conese,Sante Di Gioia
出处
期刊:CRC Press eBooks
[CRC Press]
日期:2024-11-01
卷期号:: 134-159
被引量:6
标识
DOI:10.1201/9781003300588-6
摘要
Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] is the main active phytopharmaceutical agent of turmeric, the rhizome of Curcuma longa L. It exhibits a wide range of pharmacological activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, and wound healing effects. For these reasons, curcumin is a promising candidate to manage or control inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease, affecting several million individuals worldwide. However, the major obstacles of using curcumin as an anti-inflammatory and anticancer agent are represented by its low stability, solubility, and bioavailability. Liposomes and exosome-like nanoparticles (of mammalian and plant origin) have been conceived to overcome these hurdles and deliver curcumin to intestinal epithelial cells as well as the immune cells in the intestine. Therefore, using liposomes and exosomes-like nanoparticles loaded with curcumin as a targeted therapy in IBD is suggested to be beneficial. In this chapter, we will present liposome and exosome-like nanoparticles delivery systems to treat IBD, highlighting that more in-depth research is warranted to verify if these curcumin-based nanoformulations will have a therapeutic impact.
科研通智能强力驱动
Strongly Powered by AbleSci AI